Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Enoxolone→

Enoxolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
471-53-4
Molecular formula
C30H46O4
Molecular weight
470.7 g/mol
Drug class
Glycyrrhetinic acid (licorice-derived triterpenoid)anti-inflammatory agent
Mechanism of action
A triterpenoid with reported anti-inflammatory, antiallergic, antibacterial and antiviral properties. Its actions are multi-target and are not adequately described by a single validated molecular mechanism.
Indications / reported uses
  • Topical use for allergic or infectious skin inflammation
  • Oral use has been described in relation to mineralocorticoid-like effects and electrolyte regulation; authorised indication depends on formulation and jurisdiction

Sources: NLM MeSH — Glycyrrhetinic Acid (includes enoxolone as an entry term) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Enoxolone Environmental Risk Assessment (ERA) (the Enoxolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.